Treatment with ibrutinib also eliminates skin prick test reactivity and IgE-mediated basophil activation test (BAT) responses to aeroallergens in CLL patients (Dispenza et al., 2017; Regan et al., 2017). The gene discussed is IGHE; the disease is B-cell chronic lymphocytic leukemia.